Form 4: Immunocore CFO Receives Equity Compensation

Immunocore Holdings plc's Chief Financial Officer, Travis Alan Coy, was granted 33,353 restricted share units and 95,637 employee share options.

Summary

• Travis Alan Coy, Chief Financial Officer of Immunocore Holdings plc, was granted equity awards on February 17, 2026.
• The awards include 33,353 Restricted Share Units (RSUs), each representing a contingent right to receive one Ordinary Share.
• The RSUs will vest in four equal annual installments, with the first vesting date on February 17, 2027, subject to continuous service.
• Additionally, 95,637 Employee Share Options were granted with an exercise price of $32.38 per share.
• The options will vest 25% on February 17, 2027, followed by quarterly installments of 6.25% thereafter, also contingent on continuous service.
• The Employee Share Options have an expiration date of February 16, 2036.
• Ordinary Shares may be represented by American Depositary Shares, with each ADS representing one Ordinary Share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value and ensuring executive retention.

Positives

• The equity grants align the Chief Financial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• The awards serve as a mechanism to retain a key executive, ensuring continuity in leadership.

Negatives

• No direct negatives are indicated by this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedules for both the Restricted Share Units and Employee Share Options extend several years into the future, indicating an expectation of continued service from the Chief Financial Officer and aligning his long-term incentives with the company's performance.

Industry Context

StockSavvy.ai notes that granting equity awards such as RSUs and stock options is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. This approach aligns executive compensation with shareholder value creation over the long term, a common strategy in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with common practices observed in comparable biotech companies such as Moderna (MRNA) or BioNTech (BNTX) for executive retention and performance alignment.
• The specific amounts granted are within typical ranges for a Chief Financial Officer at a company of Immunocore's stage and market capitalization, reflecting competitive compensation packages designed to secure top talent.

Stakeholder Impact

• Shareholders: The grants align the CFO's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to competitive compensation practices.

Next Steps

• Continued service of the Chief Financial Officer to meet vesting conditions for RSUs and stock options.
• Future vesting events for the granted equity awards as per the established schedule.

Key Dates

Keywords

Immunocore, IMCR, Form 4, Equity Compensation, Restricted Share Units, RSU, Stock Options, Employee Options, CFO, Insider Transaction, Executive Compensation